CN116549584B - Traditional Chinese medicine composition for treating bone marrow suppression and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating bone marrow suppression and preparation method thereof Download PDFInfo
- Publication number
- CN116549584B CN116549584B CN202310584393.4A CN202310584393A CN116549584B CN 116549584 B CN116549584 B CN 116549584B CN 202310584393 A CN202310584393 A CN 202310584393A CN 116549584 B CN116549584 B CN 116549584B
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- decoction
- medicine composition
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 115
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 210000001185 bone marrow Anatomy 0.000 title claims abstract description 34
- 230000001629 suppression Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 206010065553 Bone marrow failure Diseases 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 235000021419 vinegar Nutrition 0.000 claims abstract description 14
- 239000000052 vinegar Substances 0.000 claims abstract description 14
- 235000006533 astragalus Nutrition 0.000 claims abstract description 8
- 241001061264 Astragalus Species 0.000 claims abstract description 5
- 241000405414 Rehmannia Species 0.000 claims abstract description 5
- 210000004233 talus Anatomy 0.000 claims abstract description 5
- 244000061520 Angelica archangelica Species 0.000 claims abstract description 4
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 4
- 244000164480 Curcuma aromatica Species 0.000 claims abstract description 4
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 4
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims abstract description 4
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 4
- 241000233932 Sparganium Species 0.000 claims abstract description 4
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims abstract description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 4
- 235000019509 white turmeric Nutrition 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 45
- 239000000463 material Substances 0.000 claims description 14
- 238000009835 boiling Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 240000005856 Lyophyllum decastes Species 0.000 claims description 7
- 235000013194 Lyophyllum decastes Nutrition 0.000 claims description 7
- 239000003292 glue Substances 0.000 claims description 7
- 241000270666 Testudines Species 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 241000382455 Angelica sinensis Species 0.000 claims description 3
- 241000045403 Astragalus propinquus Species 0.000 claims description 3
- 241000913745 Spatholobus Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 1
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 abstract description 14
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 206010006187 Breast cancer Diseases 0.000 abstract description 5
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 5
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 abstract description 4
- 241000282994 Cervidae Species 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 102000001554 Hemoglobins Human genes 0.000 description 11
- 108010054147 Hemoglobins Proteins 0.000 description 11
- 210000000440 neutrophil Anatomy 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 238000004820 blood count Methods 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 108091008039 hormone receptors Proteins 0.000 description 4
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 3
- 208000006083 Hypokinesia Diseases 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 208000026535 luminal A breast carcinoma Diseases 0.000 description 2
- 208000026534 luminal B breast carcinoma Diseases 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- 241001550206 Colla Species 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 201000007741 female breast cancer Diseases 0.000 description 1
- 201000002276 female breast carcinoma Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for treating bone marrow suppression caused by CDK4/6 targeted drugs and a preparation method thereof, wherein the traditional Chinese medicine composition comprises the following components in parts by weight: 45g of astragalus, 9g of angelica, 9g of vinegar curcuma zedoary, 9g of vinegar burreed tuber, 12g of deer horn gum and 30g of prepared rhizome of rehmannia. The traditional Chinese medicine composition for treating the bone marrow depression has the functions of tonifying qi, activating blood, replenishing essence and replenishing marrow, can be used for treating the bone marrow depression caused by various antitumor drugs, particularly for treating the blood image depression induced by CDK4/6 inhibitors, does not need to stop taking CDK4/6 targeted drugs when the traditional Chinese medicine composition for treating the bone marrow depression is taken, and does not influence the curative effect of treating breast cancer.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating bone marrow suppression and a preparation method thereof.
Background
Breast cancer has become the first malignancy in female worldwide. The Estrogen Receptor (ER), the Progestin Receptor (PR), the human epidermal growth factor receptor (HER-2) and Ki67 can be generally classified into 4 subtypes of the luminal A type, the luminal B type, the HER-2 over-expression type and the triple-negative breast cancer according to the expression condition of the same. The proportion of Hormone Receptor (HR) positive patients is maximum, about 70%, and two subtypes of the luminal A type and the luminal B type are included. For HR positive breast cancer patients, endocrine medicine is an important treatment mode; in recent years, with the progress of drug therapy, methods of combining cyclin-dependent kinase 4 and 6 (cyclindependent kinase and 6, cdk 4/6) targeted drugs and endocrine have been increasingly applied to HR positive breast cancer patients, including postoperative adjuvant therapy, first-line and later-line therapies for advanced patients, etc., and representative drugs include darcinril, pie Bai Xili, abbe's, etc.
Although CDK4/6 targeted drugs have improved the efficacy of breast patients well, adverse reactions caused by them also make many patients intolerable, some patients can lose weight, some patients can only select drug withdrawal, and finally, these patients cannot enjoy the results caused by new drugs. Myelosuppression is one of the most common adverse reactions of CDK4/6 targeted drugs, and is characterized by neutropenia, leucocyte, hemoglobin decrease and thrombocytopenia, and is mostly accompanied with symptoms such as anorexia, tiredness and hypodynamia with or without abdominal distension, diarrhea and the like, and belongs to the patients with qi deficiency and blood stasis and malnutrition in the marrow sea.
Studies reported that darcilii resulted in 97.1%, 97.9%, 61.3% and 565.3% of the occurrence of leukopenia, granulocyte, hemoglobin, platelet decrease, respectively; the incidence of arbelide leading to a decrease in leukocytes, granulocytes, hemoglobin, platelets is 36.8%, 44.6%, 22.9% and 12.2%, respectively; the incidence of the group Bai Xili leading to the drop in leukocytes, granulocytes, hemoglobin, platelets was 39%, 79.5%, 24.1% and 15.5%, respectively. In addition, since CDK4/6 targeted drugs are all in oral dosage form and need to be taken daily, once myelosuppression occurs, if traditional hematopoiesis drugs such as granulocyte colony stimulating factor, erythropoietin or platelet growth promoting factor are adopted, CDK4/6 targeted drugs need to be deactivated, and the effect of the drugs is also influenced. Traditional Chinese medicine has many advantages for bone marrow protection, and various researches prove that the traditional Chinese medicine can help tumor patients to avoid bone marrow suppression, but the researches are concentrated in the traditional chemotherapy field, and the traditional Chinese medicine lacks effective data support for the emerging medicine of CDK4/6 inhibitor.
Disclosure of Invention
The present invention is directed to solving at least one of the technical problems existing in the related art. The invention provides a traditional Chinese medicine composition for treating bone marrow suppression, which comprises the following components in parts by weight: 45g of astragalus, 9g of angelica, 9g of vinegar curcuma zedoary, 9g of vinegar burreed tuber, 12g of deer horn gum and 30g of prepared rhizome of rehmannia.
The invention provides a traditional Chinese medicine composition for treating bone marrow suppression, which comprises the following components in parts by weight: 15g of suberect spatholobus stem, 12g of vinegar turtle shell and 9g of fried chicken's gizzard-membrane.
The traditional Chinese medicine composition for treating bone marrow suppression provided by the invention is one of tablets, capsules, granules, syrup, paste, suspension or pills.
The invention also provides a preparation method of the traditional Chinese medicine composition for treating bone marrow suppression, which comprises the following steps:
s1: soaking 45g of astragalus membranaceus, 9g of angelica sinensis, 9g of rhizoma curcumae, 9g of rhizoma sparganii preparata, 30g of radix rehmanniae preparata, 15g of caulis spatholobi, 12g of vinegar turtle shell and 9g of fried chicken's gizzard-membrane in water at 0-20 ℃ for 20-60 min to obtain a mixed traditional Chinese medicine material;
s2: performing primary decoction on the mixed traditional Chinese medicine materials to obtain first decoction liquid, taking 150-250 mL of the first decoction liquid, and filtering to obtain first decoction liquid;
s3: adding water into the rest first decoction liquid medicine to obtain second decoction liquid medicine, performing second-stage decoction on the second decoction liquid medicine to obtain third decoction liquid medicine, taking 150-250 mL of the third decoction liquid medicine, and filtering to obtain second liquid medicine;
s4: and uniformly mixing the first liquid medicine and the second liquid medicine to obtain a third liquid medicine, adding 12g of deer-horn glue into the third liquid medicine, and obtaining the traditional Chinese medicine composition after the deer-horn glue is melted.
According to the preparation method of the traditional Chinese medicine composition for treating bone marrow suppression, the water surface height in the mixed traditional Chinese medicine material is required to be 2-3 cm higher than that of the medicine.
According to the preparation method of the traditional Chinese medicine composition for treating bone marrow suppression, the first-stage decoction comprises the following steps: boiling the mixed traditional Chinese medicine materials with strong fire, and then boiling with slow fire for 20-30 min to obtain a first decoction.
According to the preparation method of the traditional Chinese medicine composition for treating bone marrow suppression, the operation steps of the secondary decoction are as follows: boiling the second decoction liquid by strong fire, and then boiling by slow fire for 15-20 min to obtain a third decoction liquid.
The above technical solutions in the embodiments of the present invention have at least one of the following technical effects:
the traditional Chinese medicine composition for treating the bone marrow depression has the functions of tonifying qi, activating blood, replenishing essence and replenishing marrow, can be used for treating the bone marrow depression caused by various antitumor drugs, has obvious relieving effect on symptoms such as hypodynamia, fatigue and the like, particularly has the effect of reducing blood images induced by CDK4/6 inhibitors, has simple formula and obvious medicine effect, and does not need to stop taking CDK4/6 targeted drugs when the traditional Chinese medicine composition for treating the bone marrow depression is taken, and can not influence the curative effect of treating breast cancer.
Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention.
Drawings
In order to more clearly illustrate the invention or the technical solutions of the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described, and it is obvious that the drawings in the description below are some embodiments of the invention, and other drawings can be obtained according to these drawings without inventive effort for a person skilled in the art.
Fig. 1 is a graph showing the comparison of the white blood cell count before and after administration of a Chinese medicinal composition for treating bone marrow suppression.
Fig. 2 is a graph showing comparison of neutrophil counts before and after administration of a Chinese medicinal composition for treating myelosuppression.
Fig. 3 is a graph showing comparison of hemoglobin counts before and after administration of a Chinese medicinal composition for treating myelosuppression.
Fig. 4 is a graph showing comparison of platelet counts before and after administration of a Chinese medicinal composition for treating myelosuppression.
Detailed Description
For the purpose of making the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings, and it is apparent that the described embodiments are some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention. The following examples are illustrative of the invention but are not intended to limit the scope of the invention.
In the description of embodiments of the present invention, the terms "first," "second," and "third" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance.
In the description of the present specification, a description referring to terms "one embodiment," "some embodiments," "examples," "specific examples," or "some examples," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the embodiments of the present invention. In this specification, schematic representations of the above terms are not necessarily directed to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, the different embodiments or examples described in this specification and the features of the different embodiments or examples may be combined and combined by those skilled in the art without contradiction.
The present invention provides a Chinese medicinal composition for treating bone marrow depression and a preparation method thereof, which are described below with reference to fig. 1 to 4:
the invention provides a traditional Chinese medicine composition for treating bone marrow suppression, which comprises the following components in parts by weight: 45g of astragalus, 9g of angelica, 9g of vinegar curcuma zedoary, 9g of vinegar burreed tuber, 12g of deer horn gum and 30g of prepared rhizome of rehmannia.
The invention provides a traditional Chinese medicine composition for treating bone marrow suppression, which comprises the following components in parts by weight: 15g of suberect spatholobus stem, 12g of vinegar turtle shell and 9g of fried chicken's gizzard-membrane.
The medical principle of the invention is as follows: astragalus and prepared rhizome of rehmannia are monarch drugs for tonifying qi, generating blood, filling marrow and replenishing blood; matching with colla cornus cervi, radix Angelicae sinensis, vinegar carapax et Plastrum Testudinis, and caulis Spatholobi to assist principal drug to supplement qi and blood, and replenishing essence and marrow as ministerial drug; the rhizoma sparganii with vinegar and the rhizoma curcumae with vinegar are used as adjuvant drugs for promoting blood circulation by removing blood stasis, removing food retention and eliminating mass, and the fried chicken's gizzard-skin is used for promoting digestion and astringing essence.
The traditional Chinese medicine composition for treating bone marrow suppression provided by the invention is one of tablets, capsules, granules, syrup, paste, suspension or pills.
The invention also provides a preparation method of the traditional Chinese medicine composition for treating bone marrow suppression, which comprises the following steps:
s1: soaking 45g of astragalus membranaceus, 9g of angelica sinensis, 9g of rhizoma curcumae, 9g of rhizoma sparganii preparata, 30g of radix rehmanniae preparata, 15g of caulis spatholobi, 12g of vinegar turtle shell and 9g of fried chicken's gizzard-membrane in water at 0-20 ℃ for 20-60 min to obtain a mixed traditional Chinese medicine material;
s2: performing primary decoction on the mixed traditional Chinese medicine materials to obtain first decoction liquid, taking 150-250 mL of the first decoction liquid, and filtering to obtain first decoction liquid;
s3: adding water into the rest first decoction liquid medicine to obtain second decoction liquid medicine, performing second-stage decoction on the second decoction liquid medicine to obtain third decoction liquid medicine, taking 150-250 mL of the third decoction liquid medicine, and filtering to obtain second liquid medicine;
s4: and uniformly mixing the first liquid medicine and the second liquid medicine to obtain a third liquid medicine, adding 12g of deer-horn glue into the third liquid medicine, and obtaining the traditional Chinese medicine composition after the deer-horn glue is melted.
According to the preparation method of the traditional Chinese medicine composition for treating bone marrow suppression, the water surface height in the mixed traditional Chinese medicine material is required to be 2-3 cm higher than that of the medicine.
According to the preparation method of the traditional Chinese medicine composition for treating bone marrow suppression, the first-stage decoction comprises the following steps: boiling the mixed traditional Chinese medicine materials with strong fire, and then boiling with slow fire for 20-30 min to obtain a first decoction.
According to the preparation method of the traditional Chinese medicine composition for treating bone marrow suppression, the operation steps of the secondary decoction are as follows: boiling the second decoction liquid by strong fire, and then boiling by slow fire for 15-20 min to obtain a third decoction liquid.
In one embodiment, to demonstrate the pharmacological effect of the traditional Chinese medicine composition for treating myelosuppression provided by the invention, the inventor carries out clinical observation on 15 female breast cancer patients who cause myelosuppression after taking CDK4/6 targeted drugs; the ages were at least 35 years old and at most 72 years old, all patients who developed myelosuppression following CDK4/6 targeted drug administration.
The treatment method comprises the following steps: the traditional Chinese medicine composition for treating bone marrow suppression provided by the invention is taken twice per day, 190-210 mL is taken each time, and the total time is 21 days in one treatment course.
Efficacy assessment index:
1. white blood cell count: compared with the traditional Chinese medicine composition for treating bone marrow suppression, the white blood cell count is changed before the traditional Chinese medicine composition is taken;
2. neutrophil count: compared with the traditional Chinese medicine composition for treating bone marrow suppression, the invention has the advantages that the neutrophil count is changed;
3. hemoglobin count: compared with the traditional Chinese medicine composition for treating bone marrow suppression, the invention has the advantages that the hemoglobin count is changed;
4. platelet count: compared with the traditional Chinese medicine composition for treating bone marrow suppression, the invention has the advantages that the platelet count is changed.
Treatment results:
as shown in figure 1, before the administration of the traditional Chinese medicine composition for treating bone marrow suppression, the white blood cell count of a patient is reduced to be lower than the normal value by 4.0109/L, increased leucocyte appears at week 1 after administration of the Chinese medicine, and both weeks 2 and 3 are within normal range.
As shown in figure 2, the neutrophil count of the patient is reduced by 2.0 below the normal value before taking the traditional Chinese medicine composition for treating bone marrow suppressionAfter taking the traditional Chinese medicine, the neutrophil rise occurs at the 1 st week, and the normal range is reached at the 2 nd week and the 3 rd week.
As shown in figure 3, the hemoglobin count of a patient is reduced and is lower than the lower limit of 115g/L of a normal value before taking the traditional Chinese medicine composition for treating bone marrow suppression, and the hemoglobin count is gradually increased after taking the traditional Chinese medicine composition.
As shown in FIG. 4, the platelet count of the patient is reduced by less than 75 before administration of the Chinese medicinal composition for treating bone marrow suppression109/L, which is a level 2 adverse reaction, is increased to 90 +.1 weeks after taking the Chinese medicine>109/L (level 1 adverse reaction), 100 +.2 and 3 weeks up>109/L level or more.
In summary, the invention provides a traditional Chinese medicine composition for treating myelosuppression, which can effectively treat myelosuppression after CDK4/6 targeted drugs.
Among them, typical clinical cases are as follows:
1. bi Mou, female, 55 years old, showed a drop in neutrophils to 0.8 following CDK4/6 targeted drug administration109/L, hemoglobin decreased to 75g/L, and after taking the medicine for 7 days, neutrophils recovered to 1.6 +.>109/L, hemoglobin was recovered to 92g/L.
2. Zhang Mou, female, 65 years old, showed a drop in neutrophil to 1.2 following CDK4/6 targeted drug administration109/L, platelet drop to 50 +.>109/L, after taking the medicine for 10 days, neutrophils return to 1.8 +.>109/L, platelet recovery to 95 +.>109/L。
3. Zhao Mou, female, 47 years old, showed a drop in neutrophil to 1.6 following CDK4/6 targeted drug administration109/L, platelets drop to 90 +.>109/L, the period of taking the medicine is always maintained between the level 1 adverse reaction and the normal range, no adverse reaction above level 3 occurs, CDK4/6 targeted medicine is continuously used, and no medicine stopping or reduction is carried out.
The results show that the traditional Chinese medicine composition for treating bone marrow suppression provided by the invention can effectively treat bone marrow suppression caused by CDK4/6 inhibitor medicines, and has obvious relieving effects on symptoms such as hypodynamia, fatigue and the like. The prescription is simple, but the drug effect is obvious.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and are not limiting; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims (6)
1. The traditional Chinese medicine composition for treating bone marrow suppression is characterized by comprising the following components in parts by weight:
45g of astragalus, 9g of angelica, 9g of vinegar-processed curcuma zedoary, 9g of vinegar-processed sparganium, 12g of deer-horn glue, 30g of prepared rehmannia root, 15g of suberect spatholobus stem, 12g of vinegar-processed turtle shell and 9g of fried chicken's gizzard-membrane.
2. The traditional Chinese medicine composition for treating bone marrow suppression according to claim 1, wherein the dosage form of the traditional Chinese medicine composition is one of a tablet, a capsule, a granule, a syrup, a paste, a suspension or a pill.
3. A method for preparing a traditional Chinese medicine composition for treating myelosuppression according to any one of claims 1-2, comprising the following steps:
s1: soaking 45g of astragalus membranaceus, 9g of angelica sinensis, 9g of rhizoma curcumae, 9g of rhizoma sparganii preparata, 30g of radix rehmanniae preparata, 15g of caulis spatholobi, 12g of vinegar turtle shell and 9g of fried chicken's gizzard-membrane in water at 0-20 ℃ for 20-60 min to obtain a mixed traditional Chinese medicine material;
s2: performing primary decoction on the mixed traditional Chinese medicine materials to obtain first decoction liquid, taking 150-250 m L of the first decoction liquid, and filtering to obtain first decoction liquid;
s3: adding water into the rest first decoction liquid to obtain a second decoction liquid, performing secondary decoction on the second decoction liquid to obtain a third decoction liquid, and filtering the third decoction liquid to obtain a second liquid; s4: and uniformly mixing the first liquid medicine and the second liquid medicine to obtain a third liquid medicine, adding 12g of deer-horn glue into the third liquid medicine, and obtaining the traditional Chinese medicine composition after the deer-horn glue is melted.
4. The method for preparing a Chinese medicinal composition for treating bone marrow depression according to claim 3, wherein the water level in the mixed Chinese medicinal materials is 2-3 cm higher than that of the medicines.
5. The method for preparing a traditional Chinese medicine composition for treating myelosuppression according to claim 3, wherein the primary decoction comprises the following steps: boiling the mixed traditional Chinese medicine materials with strong fire, and then boiling with slow fire for 20-30 min to obtain a first decoction.
6. The method for preparing a traditional Chinese medicine composition for treating myelosuppression according to claim 3, wherein the operation steps of the secondary decoction are as follows: boiling the second decoction liquid by strong fire, and then boiling by slow fire for 15-20 min to obtain a third decoction liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310584393.4A CN116549584B (en) | 2023-05-23 | 2023-05-23 | Traditional Chinese medicine composition for treating bone marrow suppression and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310584393.4A CN116549584B (en) | 2023-05-23 | 2023-05-23 | Traditional Chinese medicine composition for treating bone marrow suppression and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116549584A CN116549584A (en) | 2023-08-08 |
| CN116549584B true CN116549584B (en) | 2024-01-19 |
Family
ID=87498023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310584393.4A Active CN116549584B (en) | 2023-05-23 | 2023-05-23 | Traditional Chinese medicine composition for treating bone marrow suppression and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116549584B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612248A (en) * | 2009-07-10 | 2009-12-30 | 王兆彩 | The myelosuppressive Chinese medicine of a kind of treatment |
| CN108653671A (en) * | 2018-06-28 | 2018-10-16 | 辽宁传明健康产业有限公司 | A kind of anticancer drug and preparation method thereof |
| CN108686034A (en) * | 2018-07-09 | 2018-10-23 | 姚大鹏 | The Chinese medicine composition and preparation method of bone marrow suppression after a kind of antagonism chemotherapy of tumors |
| CN110101816A (en) * | 2019-05-14 | 2019-08-09 | 林畅 | Warm sun dredging collateral, Chinese medicine composition of inrigorating qi and promoting blood circulation and its preparation method and application |
| CN113332326A (en) * | 2021-06-15 | 2021-09-03 | 张家港市中医医院 | Traditional Chinese medicine composition for relieving bone marrow suppression after chemotherapy and preparation method thereof |
-
2023
- 2023-05-23 CN CN202310584393.4A patent/CN116549584B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612248A (en) * | 2009-07-10 | 2009-12-30 | 王兆彩 | The myelosuppressive Chinese medicine of a kind of treatment |
| CN108653671A (en) * | 2018-06-28 | 2018-10-16 | 辽宁传明健康产业有限公司 | A kind of anticancer drug and preparation method thereof |
| CN108686034A (en) * | 2018-07-09 | 2018-10-23 | 姚大鹏 | The Chinese medicine composition and preparation method of bone marrow suppression after a kind of antagonism chemotherapy of tumors |
| CN110101816A (en) * | 2019-05-14 | 2019-08-09 | 林畅 | Warm sun dredging collateral, Chinese medicine composition of inrigorating qi and promoting blood circulation and its preparation method and application |
| CN113332326A (en) * | 2021-06-15 | 2021-09-03 | 张家港市中医医院 | Traditional Chinese medicine composition for relieving bone marrow suppression after chemotherapy and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 吴复苍.常见病遣方用药规律.人民军医出版社,2015,(第1版),30. * |
| 王昌俊教授治疗化疗相关性骨髓抑制的经验;林举择;环球中医药;第11卷(第8期);1310-1312 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116549584A (en) | 2023-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102342992A (en) | Chinese medicinal composition for treating insomnia and preparation method of preparation thereof | |
| CN102302608B (en) | Chinese medicinal composition for treating anemia and preparation method thereof | |
| CN108619355A (en) | A kind of antitumor Chinese and preparation method thereof | |
| CN116549584B (en) | Traditional Chinese medicine composition for treating bone marrow suppression and preparation method thereof | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN103223149B (en) | Chinese herb medicine composition for treating lung cancer | |
| CN102038821B (en) | Method for preparing medicinal composition for treating dysmenorrhea | |
| CN101444583A (en) | Medicament for curing neurasthenia | |
| CN107412661A (en) | A kind of Chinese medicine composition for treating impotence, premature ejaculation and preparation method thereof | |
| CN1277573C (en) | Medication for curing ulcerationd of oral cavity | |
| CN101983666A (en) | Traditional Chinese medicine composition for treating rheumatism and preparation method thereof | |
| CN101642485B (en) | Application of medical composition containing astragalus root in preparing medicine for treating leucopenia and Henoch-Schonlein Purpura | |
| CN100588413C (en) | Traditional Chinese medicine composition for treating irritable bowel syndrome and its preparation method | |
| CN106581599A (en) | Drug for treating rheumatism and preparation method thereof | |
| CN103948784A (en) | Preparation for treating thyroid enlargement, activating stagnation and removing stasis and preparation method thereof | |
| CN114984160B (en) | Mongolian medicine for treating alcoholic liver disease | |
| CN107050187A (en) | A kind of Chinese medicine composition for treating impotence, premature ejaculation and preparation method thereof | |
| CN101129796A (en) | Pharmaceutical composition used for chronic atrophic gastritis and processes for producing same | |
| CN1256083C (en) | Medicine for boosting qi and nourishing blood and its prepatation method | |
| CN104771627A (en) | Traditional Chinese medicine composition for treating uterine prolapse | |
| CN108714165A (en) | A kind of improvement gout composition, preparation and preparation method thereof | |
| CN104189846A (en) | Traditional Chinese medicine composition used as radiotherapy and chemotherapy sensitizing agent and preparation method thereof | |
| CN104689246B (en) | A kind of medicine for the treatment of gastric cancer | |
| CN113041333A (en) | Traditional Chinese medicine for treating schizophrenia and preparation method thereof | |
| CN104473957B (en) | A kind of Chinese medicine monomer compositions for blood fat reducing and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |